CA
ICPT

CoreCap Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

CoreCap Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$62 Buy
+5
New +$71 ﹤0.01% 2331
2022
Q3 		– Sell
-5
Closed – – 2255
2022
Q2 		$0 Buy
+5
New +$80 ﹤0.01% 2328
2022
Q1 		– Sell
-5
Closed -$1K – 2252
2021
Q4 		$1K Buy
+5
New +$84 ﹤0.01% 2332

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CoreCap Advisors's ICPT Position: Q4 2022 in Review

CoreCap Advisors opened a new position in Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022: 5 shares worth $62. The stake represents ﹤0.01% of the portfolio and ranks #2331 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in ICPT as recently as Q2 2022.

CoreCap Advisors first reported a position in ICPT in Q4 2021 and has held it in 3 quarters since. The position peaked at $1K in Q4 2021. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

  • CoreCap Advisors held 5 shares of Intercept Pharmaceuticals, Inc. worth $62 as of Q4 2022.
  • Intercept Pharmaceuticals, Inc. was a new CoreCap Advisors position in Q4 2022.
  • Intercept Pharmaceuticals, Inc. made up ﹤0.01% of CoreCap Advisors's portfolio in Q4 2022, its #2331 holding.
  • CoreCap Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2021 and has held it in 3 quarters since.
  • CoreCap Advisors's Intercept Pharmaceuticals, Inc. position peaked at $1K in Q4 2021.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on CoreCap Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.